抗β_2-受体自身抗体在心肌梗死急性期的动态变化  

Dynamic Changes of Autoantibody Against The β_2-Receptor in Patients with Acute Myocardial Infarction

作　　者：陈牧雷[1] 张麟[1] 刘秀兰[1] 刘瑞红[2] 张磊[3] 杨新春[1] 

机构地区：[1]首都医科大学附属北京朝阳医院心脏中心,北京100020 [2]山西医科大学,太原030001 [3]北京市第六医院内科,北京100007

出　　处：《中国医药导刊》2004年第1期28-30,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:了解抗β2-受体的自身抗体在急性心肌梗死(AMI)时的变化规律。方法:以合成的人心脏β2-受体细胞外第二环表位肽段172-197氨基酸序列作为抗原,应用酶联免疫吸附(ELISA)方法,检测41例AMI患者,发病24小时、7天、2～4周时,血清中抗β2-受体自身抗体的阳性率,并与61例正常人的检测结果进行对比。结果:心肌梗死患者急性期抗β2-受体自身抗体的阳性率显著高于对照组(P<0.05);心肌梗死发病24小时时抗β2-受体自身抗体的阳性率(29.3％)明显低于发病2-4周时(56.1％)的检测结果(P<0.05);心肌梗死急性期心功能killip-1级者与killip-2级者比较,抗β2-受体自身抗体的阳性率无显著性差异。结论:抗β2-受体自身抗体存在于AMI患者血清中,且在发病2～4周内逐渐升高。该抗体的产生与心肌梗死急性期心功能状态无明显的相关性。Objective: To learn the law of development of the autoantibody against the β2-adrenergic receptor (β2-receptor)in patients with acute myocardial infarction. Methods: By ELISA method, synthetic peptides corresponding to the amino acids se- quence172-197 of the second extra cellular loops of the β2-receptor were used as the antigens to screen the positive sera from 41 AMI patients on 24 hours, 7 days and 2-4 weeks of symptoms onset, and the testing result was compared with those of the 61 healthy donors.Results:The positive ratio of β2-autoantibody of patients with myocardial infarction at acute stage was significantly higher than those in NC group(P<0.05);the positive ratio of β2-autoantibody of patients on 24 hours after AMI (29.3%) was significantly lower than those of the patients 2-4 weeks after AMI(56.l%,P<0.05). There was no significant difference of the positive ratio of β2-autoan- tibody between the cardiac function class killip-land class killip-2at acute stage of myocardial infarction.Conclusion: The β2-autoantibody exists in the serum of AMI patients, and gradually elevates in 2 to 4 weeks after symptom onset. The generation of β2-autoantibody has no obvious relationship with the stage of cardiac function in the acute stage of myocardial infarction.

关 键 词：Β2-受体 自身抗体 心肌梗死 急性期 酶联免疫吸附 检测 

分 类 号：R542.22[医药卫生—心血管疾病] R446.62[医药卫生—内科学]